Skip to content
Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Q3’25 Survey: What are Psychedelics Investors Excited About?

Q3’25 Survey: What are Psychedelics Investors Excited About?

  • Post published:October 21, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Psychedelic Funding Update: Q3 2025

Psychedelic Funding Update: Q3 2025

  • Post published:October 16, 2025
  • Post category:Analysis/Pα+
Read more about the article Q2 2025: Oregon Psilocybin Services Update

Q2 2025: Oregon Psilocybin Services Update

  • Post published:October 10, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Psychedelic Investor Survey Q3 2025

Psychedelic Investor Survey Q3 2025

  • Post published:October 7, 2025
  • Post category:Analysis/News
Read more about the article Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

  • Post published:September 22, 2025
  • Post category:Analysis/News/Pα+
Read more about the article UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

UK Royal College of Psychiatrists Weighs In: Promise in Psychedelics, But Hype Mustn’t Outpace Evidence

  • Post published:September 19, 2025
  • Post category:Analysis/News/Pα+
Read more about the article Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

  • Post published:September 16, 2025
  • Post category:Analysis
Read more about the article Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

  • Post published:September 8, 2025
  • Post category:Analysis/News/Pα+
Read more about the article BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

BREAKING: FDA Publishes Lykos Therapeutics’ MDMA Complete Response Letter (CRL)

  • Post published:September 4, 2025
  • Post category:Analysis/News
Read more about the article Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

Psychedelic Researchers Respond to FDA’s Push to Reduce Animal Testing

  • Post published:September 3, 2025
  • Post category:Analysis/News/Pα+

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More